We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Stealth BioTherapeutics announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for elamipretide for the treatment of Barth syndrome.
Renal pelvis dilatation (RPD) at the fetal anomaly scan (FAS) and persistent dilatation in later pregnancy or postpartum is associated with an increased risk for hospital admission in early childhood...